RNASET2 and ovarian carcinoma: However, some notes of caution on the above-mentioned in vivo data stemmed from the use of a poorly known ovarian cancer cell line with an RNASET2-overexpression experimental plan, which might have biased the observed data by establishing an unphysiological setting.